

BC PharmaCare Drug Information

The drug below is being considered for coverage under the BC PharmaCare program. PharmaCare is a government-funded drug plan that helps B.C. residents with the cost of eligible prescription drugs and medical supplies. For more information about PharmaCare, visit the [PharmaCare website](#).

PharmaCare reviews each drug for treating a specific illness or medical condition (also called an “indication”). If PharmaCare decides to cover a drug, that coverage applies only to the indication(s) specified. In some cases, PharmaCare covers a drug only for people who have not responded to other drugs that treat the same indication.

More information about the PharmaCare drug review process is provided on the last page of this document.

Drug information	
Generic name (scientific name)	vamorolone
Brand name	Agamree®
Manufacturer	Kye Pharmaceuticals Inc.
Indication	For the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older.
Has the drug been reviewed by CDA-AMC, or will CDA-AMC be reviewing it? (See note below.)	Yes For more information about the CDA-AMC Reimbursement Review (CRR) of vamorolone (Agamree®), Search the CDA-AMC Reports .
Public input start date	Wednesday, December 31, 2025
Public input closing date	Tuesday, January 27, 2026, at 11:59 pm
How is the drug taken?	Vamorolone is taken orally (through the mouth).
How often is the drug taken?	Vamorolone is taken once a day.

Drug information	
General drug and/or drug study information	<p>Duchenne muscular dystrophy (DMD) is a rare genetic condition where muscles get weaker over time because the body is unable to make a protein called dystrophin. Dystrophin is needed for muscles to function. DMD mostly affects young males and usually starts showing signs in early childhood. Children with DMD often have frequent falls, delayed growth and motor skills, and later develop problems with breathing and their heart muscles.</p> <p>Vamorolone is a steroid that works by reducing inflammation and protecting muscles.</p> <p>Studies looked at the following:</p> <ul style="list-style-type: none"> • To assess physical strength and endurance, change from baseline to 24 weeks in the following: <ul style="list-style-type: none"> ○ Time to Stand (TTSTAND) velocity ○ 6-Minute Walk Test (6MWT) ○ North Star Ambulatory Assessment (NSAA) score • Bad reactions • Serious bad reactions • Patients leaving the trial due to bad reactions • Bad reactions of special interest including behaviour changes and weight gain
Other considerations	None

Note:

CDA-AMC ([Canada's Drug Agency-L'Agence des Médicaments du Canada](#)) is a national organization that reviews drugs on behalf of Canadian public sector plans when drug manufacturers want those plans to provide coverage for the drug. For detailed information about the PharmaCare drug review process, including the role of the CDA-AMC Reimbursement Review (CRR) in that process, visit [How PharmaCare Decides Which Drugs to Cover](#).

Table of Comparators Used to Treat the Same Indication		
Generic Name (Brand Name) of Drug Comparator	Dosage Form	PharmaCare Status (if and how the drug is already covered)
vamorolone (Agamree)	Oral suspension	Under Review

Table of Comparators Used to Treat the Same Indication		
Generic Name (Brand Name) of Drug Comparator	Dosage Form	PharmaCare Status (if and how the drug is already covered)
prednisone (Winpred®, generics)	Oral tablet	Regular Benefit, subject to LCA
deflazacort	Oral tablet	Non-Benefit

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called [Canada's Drug Agency-L'Agence des médicaments du Canada \(CDA-AMC\)](#)
- what the drug costs and whether it is a good value to the citizens of B.C.
- ethical considerations related to covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare to treat similar medical conditions
- the overall cost of covering the drug

For more information about the drug review process in B.C., visit: the [How PharmaCare decides which drugs to cover](#).

This document provides information only.

It does not take the place of advice from a physician or other qualified health care provider.